Tetrabamate
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Combination of | |
---|---|
Febarbamate | Carbamate, barbiturate |
Difebarbamate | Carbamate, barbiturate |
Phenobarbital | Barbiturate |
Identifiers | |
ChEMBL | CHEMBL1909287 |
Tetrabamate (Atrium, G Tril, Sevrium) is a combination drug formulation of febarbamate, difebarbamate, and phenobarbital which was marketed in France and Spain and was used to treat anxiety and alcohol withdrawal-associated muscle tremors, agitation, and depression.[1][2][3][4] It was largely, but not completely discontinued on April 4, 1997 after over 30 years of use due to reports of hepatitis and acute liver failure.[3][4][5][6] The decision to restrict the use of the drug had been long-awaited.[6]
References[edit]
- ^ Index nominum 2000: international drug directory. Taylor & Francis US. 2000. pp. 333 & 427. ISBN 978-3-88763-075-1. Retrieved 26 November 2011.
- ^ Eugene R. Schiff; Willis C. Maddrey; Michael F. Sorrell (19 October 2011). Schiff's Diseases of the Liver. John Wiley and Sons. p. 2276. ISBN 978-1-119-95048-6. Retrieved 26 November 2011.
- ^ a b Binder D, Jost R, Flury R, Salomon F (May 1995). "[Acute liver failure following tetrabamate]". Schweizerische Medizinische Wochenschrift (in German). 125 (19): 965–9. PMID 7761807.
- ^ a b Consolidated list of products whose consumption and/or sale have been banned, withdrawn, severely restricted or not approved by governments. United Nations Publications. 2003. p. 259. ISBN 978-92-1-130230-1. Retrieved 26 November 2011.
- ^ Horsmans Y, Lannes D, Pessayre D, Larrey D (December 1994). "Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate". Journal of Hepatology. 21 (6): 1075–9. doi:10.1016/s0168-8278(05)80620-8. PMID 7699230.
- ^ a b "Severe hepatitis due to Atrium". Prescrire International. 10 (55): 150. October 2001. PMID 11824432.
Treatment of drug dependence (N07B)
|
|
---|---|
Nicotine dependence | |
Alcohol dependence | |
Opioid dependence | |
Benzodiazepine dependence | |
Amphetamine dependence | |
Cocaine dependence |
Skeletal muscle relaxants (M03)
|
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peripherally acting (primarily antinicotinic, NMJ block) |
|
||||||||||||||||
Centrally acting | |||||||||||||||||
Directly acting |
Alcohols | |
---|---|
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents | |
Monoureides | |
Neuroactive steroids |
|
Nonbenzodiazepines |
|
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: GABAergics
|
Hidden categories:
- CS1 German-language sources (de)
- Drugs that are a combination of chemicals
- Chemical articles without CAS Registry Number
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes